Inject SYMLIN under your skin (subcutaneously) just before a major meal
Tirzepatide, a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, commonly causes gastrointestinal effects including nausea, diarrhea, and constipation
Olaniyan OT, Femi A, Iliya G, Ayobami D, Godam E, Olugbenga E, et al
Not recommended for those with severe kidney disease or certain metabolic disordersconsult our medical team
Of those 15 cases, 12 were found to be possibly linked to use of GLP-1 RAs, while 3 could not be assessed due to missing clinical information
Tolerability and access, however, remain significant considerations